Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus chemotherapy with or without chidamide for first-line advanced biliary tract cancer
ChiCTR2400087443Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab, tucidinostat, gemcitabine, oxaliplatin and capecitabine in biliary cancer (3 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Safety and Objective response rate. Started Aug 2024; status: recruiting.
02
Drugs
cadonilimabtucidinostatgemcitabineoxaliplatincapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400087443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087443.